Tag: Sandoz
Sandoz: propelled by a broker increase
(CercleFinance.com) – Sandoz jumps 5% in Zurich, propelled by an increase in recommendation at UBS from ‘neutral’ to ‘buy’ on the stock of the group of generic and biosimilar medicines,…
In Austria, Sandoz accelerates the pace at its XXL penicillin factory
“We are proud to host the only large end-to-end penicillin manufacturing site in Europe. » In front of the Sandoz staff, meeting this Thursday, March 21 on the occasion of…
Sandoz: price target increased at Stifel
(CercleFinance.com) – Stifel reiterates its ‘buy’ recommendation on Sandoz with a price target raised from 40 to 42 Swiss francs, in the wake of 2024-25 EPS estimates raised by 4.4%…
Sandoz finalizes the purchase of Cimerli in advance – 03/04/2024 at 09:46
(AOF) – Sandoz (+0.72% to 28.15 Swiss francs), a major player in generic and biosimilar drugs, announces that it has finalized the acquisition of the American biosimilar Cimerli (ranibizumab-eqrn) from…
Sandoz: acquisition of Cimerli finalized
(CercleFinance.com) – Sandoz indicates that it has finalized, ahead of schedule, the acquisition of the American biosimilar Cimerli (ranibizumab-eqrn) from Coherus BioSciences, in accordance with the agreement last January for…
Coherus expected to rise sharply after the sale of its drug Cimerli to Sandoz – 01/22/2024 at 2:19 p.m.
(AOF) – Coherus BioSciences is expected to rise sharply after announcing today an agreement to sell its Cimerli (ranibizumab-eqrn) ophthalmology franchise to the Sandoz group for an initial amount of…
Sandoz: Acquisition of a biosimilar in ophthalmology
Receive the value of the day for free every morning The data collected is essential for this processing and is intended for the relevant services of BFM Bourse and, where…
Sandoz: repurchase of a biosimilar in ophthalmology
(CercleFinance.com) – Sandoz announces that it has signed an agreement to acquire the American ranibizumab biosimilar Cimerli (ranibizumab-eqrn) from Coherus BioSciences, for a payment of $170 million. Cimerli is interchangeable…
BAG proceedings against Sandoz – “Criminal risks”: Sandoz stops advertising money to doctors – News
Contents SRF Investigative revealed in May that Sandoz was paying doctors large sums of money for advertising in waiting rooms. The Federal Office of Public Health has now come to…
Sandoz: RBC initiates ‘outperformance’
(CercleFinance.com) – Royal Bank of Canada announced on Wednesday that it had initiated monitoring of Sandoz shares with an ‘outperform’ opinion and a price target of 33 Swiss francs, judging…
Worth eleven billion francs: Novartis subsidiary Sandoz begins its stock market career
Worth eleven billion francs Novartis subsidiary Sandoz begins stock market career October 4, 2023, 2:02 p.m The Swiss pharmaceutical giant Novartis is restructuring and will focus on patent-protected drugs in…
Novartis: the sky clears with the confirmation of the Sandoz split on October 4
(AOF) – Novartis (+0.07% to 92 Swiss francs) today confirmed its plan to spin off 100% of the Sandoz business. Trading of new Sandoz Group AG shares and ADRs (American…